Pyridinone derivatives and their use as positive allosteric modulators of mGluR2-receptors
The present invention relates to methods for treating or controlling schizophrenia in a mammal using compounds having the Formula (I), wherein M 1 and M 2 are defined in the application.
1. A method for treating or controlling schizophrenia in a mammal comprising administering to a patient in need thereof a compound according to the Formula (I),
a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof or an N-oxide form thereof, wherein:
M 1 is a phenyl group having at least one halo group; and
M 2 is a phenyl group substituted with at least one substituent selected from the group consisting of (C 1 -C 6 )alkyloxy, pyridinyl-(C 1 -C 6 )alkyloxy, morpholinyl-(C 1 -C 6 )alkyloxy, pyrrolidinyl-(C 1 -C 6 )alkyloxy optionally substituted with oxo, isoxazolyl-(C 1 -C 6 )alkyloxy, imidazolyl-(C 1 -C 6 )alkyloxy, tetrazolyl-(C 1 -C 6 )alkyloxy or thiazolyl-(C 1 -C 6 )alkyloxy, wherein the isoxazolyl, imidazolyl, tetrazolyl or thiazolyl rings may be optionally substituted with methyl.
2. The method of claim 1 , wherein M 1 is a phenyl group having at least one fluoro or chloro group.
3. The method of claim 1 , wherein M 1 is a phenyl group having one fluoro group and one chloro group.
4. The method of claim 1 , wherein M 1 is
5. The method of claim 1 , wherein M 2 is a phenyl group substituted with at least one (C 1 -C 6 )alkyloxy.
6. The method of claim 1 , wherein M 2 is a phenyl group substituted with a methoxy group.
7. The method of claim 1 , wherein M 2 is a phenyl group substituted with at least one tetrazolyl-(C 1 -C 6 )alkyloxy.
8. The method of claim 1 , wherein M 2 is a phenyl group substituted with
9. The method of claim 1 , wherein the compound is administered as a pharmaceutical composition comprising a therapeutically effective amount of the compound and a pharmaceutically acceptable carrier and/or excipient.